BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 8174107)

  • 1. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
    Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
    Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of p53 in Wilms' tumors.
    Takeuchi S; Bartram CR; Ludwig R; Royer-Pokora B; Schneider S; Imamura J; Koeffler HP
    Mod Pathol; 1995 Jun; 8(5):483-7. PubMed ID: 7675765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
    Bardeesy N; Beckwith JB; Pelletier J
    Cancer Res; 1995 Jan; 55(2):215-9. PubMed ID: 7812946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
    Lahoti C; Thorner P; Malkin D; Yeger H
    Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
    Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
    Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors.
    el Bahtimi R; Hazen-Martin DJ; Re GG; Willingham MC; Garvin AJ
    Mod Pathol; 1996 Mar; 9(3):238-44. PubMed ID: 8685221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 expression in Wilms' tumor: a possible role as prognostic factor.
    Beniers AJ; Efferth T; Füzesi L; Granzen B; Mertens R; Jakse G
    Int J Oncol; 2001 Jan; 18(1):133-9. PubMed ID: 11115550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
    Roberts DJ; Haber D; Sklar J; Crum CP
    Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype/phenotype correlations in Wilms' tumor.
    Huff V
    Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
    Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
    Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor.
    Barbosa AS; Hadjiathanasiou CG; Theodoridis C; Papathanasiou A; Tar A; Merksz M; Györvári B; Sultan C; Dumas R; Jaubert F; Niaudet P; Moreira-Filho CA; Cotinot C; Fellous M
    Hum Mutat; 1999; 13(2):146-53. PubMed ID: 10094551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.
    Haber DA; Buckler AJ
    New Biol; 1992 Feb; 4(2):97-106. PubMed ID: 1313285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A point mutation within exon 5 of the WT1 gene of a sporadic unilateral Wilms' tumor alters gene function.
    Guan LS; Liu JJ; Xu YH; Wang ZY
    Cancer Res; 1998 Sep; 58(18):4180-4. PubMed ID: 9751632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.
    Pelletier J; Bruening W; Li FP; Haber DA; Glaser T; Housman DE
    Nature; 1991 Oct; 353(6343):431-4. PubMed ID: 1654525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the p53 gene by PCR-SSCP in ten cases of Wilms' tumor.
    Defavery R; Lemos JA; Kashima S; Bernardes JE; Scridelli CA; Covas DT; Tone LG
    Sao Paulo Med J; 2000 Mar; 118(2):49-52. PubMed ID: 10772697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.